Compare Quest Diagnostics Inc (DGX) vs Elastic NV (ESTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Elastic NV — how do they compare? Quest Diagnostics Inc trades at $204.59 (market cap $22.80B), while Elastic NV trades at $63.31 (market cap $6.48B). The key difference: Quest Diagnostics Inc is far larger — about 3.5× Elastic NV's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| DGX | ESTC | |
|---|---|---|
Market Cap | $22.80B | $6.48B |
Sector | Health | Technology |
52-Week High | $216.02 | $94.47 |
52-Week Low | $166.42 | $43.30 |
Enterprise Value | $28.82B | $5.70B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Elastic N.V. (ESTC) trades at $62.43, up 3.64% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and projected revenue growth from $1.48B to $1.7B. Technical indicators signal bullish momentum, though RSI suggests potential overbought conditions near-term.
ESTC presents a compelling growth opportunity with 67.65% analyst buy ratings and a $72.80 consensus target, offering 16.6% upside. Key risks include ongoing legal investigations and the transition to profitability after 2025's net loss. The company's leadership in SIEM and AI capabilities supports long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
